FOLH1 and prostate neoplasm: We have already shown that the opportunities given by the SERRS approach can be successfully exploited for specifically identifying prostatic tumor cells expressing prostate specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA)26,31 or other antigens using engineered peptides25,34,35.